Immunomedics (NASDAQ:IMMU) Downgraded by BidaskClub

Immunomedics (NASDAQ:IMMU) was downgraded by equities research analysts at BidaskClub from a “buy” rating to a “hold” rating in a report released on Tuesday, BidAskClub reports.

Several other research analysts have also weighed in on IMMU. HC Wainwright lifted their price objective on shares of Immunomedics from $26.00 to $31.00 and gave the stock a “buy” rating in a research note on Friday, December 27th. Bank of America assumed coverage on shares of Immunomedics in a research note on Friday, December 20th. They set a “buy” rating and a $26.00 price objective on the stock. ValuEngine raised shares of Immunomedics from a “hold” rating to a “buy” rating in a research note on Thursday, January 9th. B. Riley set a $28.00 price objective on shares of Immunomedics and gave the stock a “buy” rating in a research note on Monday, September 30th. Finally, Cowen reissued a “buy” rating and set a $30.00 price objective on shares of Immunomedics in a research note on Tuesday, December 3rd. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $26.70.

Immunomedics stock traded down $0.37 during midday trading on Tuesday, hitting $19.20. 25,636 shares of the stock were exchanged, compared to its average volume of 2,107,071. The company has a fifty day simple moving average of $20.12 and a two-hundred day simple moving average of $16.46. Immunomedics has a 52 week low of $11.55 and a 52 week high of $22.22. The stock has a market capitalization of $3.80 billion, a PE ratio of -18.63 and a beta of 2.19. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.30.

Immunomedics (NASDAQ:IMMU) last released its quarterly earnings data on Wednesday, October 30th. The biopharmaceutical company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.09). During the same period last year, the company earned ($0.34) EPS. As a group, equities research analysts anticipate that Immunomedics will post -1.79 EPS for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in IMMU. Boxer Capital LLC lifted its holdings in shares of Immunomedics by 60.2% in the second quarter. Boxer Capital LLC now owns 6,567,000 shares of the biopharmaceutical company’s stock valued at $91,084,000 after purchasing an additional 2,467,000 shares in the last quarter. BlackRock Inc. boosted its position in shares of Immunomedics by 9.9% during the second quarter. BlackRock Inc. now owns 13,798,803 shares of the biopharmaceutical company’s stock worth $191,389,000 after buying an additional 1,239,462 shares during the period. Menora Mivtachim Holdings LTD. boosted its position in shares of Immunomedics by 181.4% during the third quarter. Menora Mivtachim Holdings LTD. now owns 1,434,900 shares of the biopharmaceutical company’s stock worth $19,027,000 after buying an additional 925,000 shares during the period. Peregrine Capital Management LLC acquired a new position in shares of Immunomedics during the third quarter worth about $11,412,000. Finally, Nuveen Asset Management LLC acquired a new position in shares of Immunomedics during the second quarter worth about $9,294,000. Hedge funds and other institutional investors own 82.81% of the company’s stock.

Immunomedics Company Profile

Immunomedics, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively.

Featured Story: Compound Annual Growth Rate (CAGR)

Analyst Recommendations for Immunomedics (NASDAQ:IMMU)

Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.